Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.89 |
| ▸ | NPC1 | O15118 | 1/20 | 0.89 |
| ▸ | CASP3 | P42574 | 1/20 | 0.89 |
| ▸ | RAB9A | P51151 | 1/20 | 0.89 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.89 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.89 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.89 |
| ▸ | DPP4 | P27487 | 1/20 | 0.80 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.73 |
| ▸ | MAPT | P10636 | 2/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.66 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.66 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.66 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.66 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.66 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.66 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.66 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8559822 | 0.98 | TDP1 (0.85) | TDP1NPC1CASP3RAB9ASENP8 | |
| SCHEMBL7426101 | 0.98 | TDP1 (0.85) | TDP1NPC1CASP3RAB9ASENP8 | |
| SCHEMBL9242650 | 0.98 | TDP1 (0.85) | TDP1NPC1CASP3RAB9ASENP8 | |
| SCHEMBL839278 | 0.94 | TDP1 (1.00) | TDP1NPC1CASP3RAB9ASENP8 | |
| SCHEMBL27463271 | 0.92 | DPP4 (0.81) | TDP1NPC1CASP3RAB9ASENP8 | |
| SCHEMBL27545788 | 0.88 | TDP1 (0.69) | TDP1NPC1CASP3RAB9ASENP8 | |
| SCHEMBL5991486 | 0.88 | DPP4 (0.73) | TDP1NPC1CASP3RAB9ASENP8 | |
| SCHEMBL7068671 | 0.87 | TDP1 (0.95) | TDP1NPC1CASP3RAB9ASENP8 | |
| SCHEMBL5993545 | 0.86 | DPP4 (0.71) | TDP1NPC1CASP3RAB9ASENP8 | |
| SCHEMBL3208131 | 0.86 | DPP4 (0.71) | TDP1NPC1CASP3RAB9ASENP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120188788-A | Application of neochamaejasme B in preparing insecticide for inducing insect nerve cell apoptosis | 四川大学 | 2025-06-24 | — | — | CN | disclosed |
| US-20230302030-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AS INHIBITORS OF RAN GTPase | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CA) | 2023-09-28 | — | — | US | disclosed |
| US-20230302030-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AS INHIBITORS OF RAN GTPase | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CA) | 2023-09-28 | — | — | US | disclosed |
| CN-108778756-B | Receptacle comprising a preparation containing at least one organic semiconductor | 默克专利有限公司 | 2021-03-02 | — | — | CN | disclosed |
| US-20200246365-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AS INHIBITORS OF RAN GTPASE | CENTRE HOSPITALIER DE L'UNIVERSITÉ DE MONTRÉAL (CA) | 2020-08-06 | — | — | US | disclosed |
| CN-105315118-A | Integrated extracting and separating method for active ingredients of Chinese stellera roots | LI YUSHAN | 2016-02-10 | — | — | CN | disclosed |
| US-7795166-B2 | Functional group-selective hydrogenation catalyst and functional group-selective hydrogenation method | N.E. CHEMCAT CORPORATION (JP) | 2010-09-14 | — | — | US | disclosed |
| US-20070155617-A1 | FUNCTIONAL GROUP-SELECTIVE HYDROGENATION CATALYST AND FUNCTIONAL GROUP-SELECTIVE HYDROGENATION METHOD | N. E. CHEMCAT CORPORATION (JP) | 2007-07-05 | — | — | US | disclosed |
| EP-0871439-B1 | SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS | AVENTIS PHARMA INC (US) | 2004-03-31 | — | — | EP | disclosed |
| US-6057369-A | USE IN THE TREATMENT OF DISEASE STATES ASSOCIATED WITH PROTEINS THAT MEDIATE CELLULAR ACTIVITY WHICH ARE CAPABLE OF BEING MODULATED BY INHIBITING A MATRIX METALLOPROTEINASE (MMP), TUMOR NECROSIS FACTOR (TNF) OR CYCLIC AMP | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 2000-05-02 | — | — | US | disclosed |
| EP-0882005-A1 | PHENOL COMPOUND HYDROXYLATION METHOD | RHODIA CHIMIE (FR) | 1998-12-09 | — | — | EP | disclosed |
| US-5843997-A | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 1998-12-01 | — | — | US | disclosed |
| EP-0871439-A1 | SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1998-10-21 | — | — | EP | disclosed |
| WO-1997029066-A1 | PHENOL COMPOUND HYDROXYLATION METHOD | RHODIA CHIMIE (FR) | 1997-08-14 | — | — | WO | disclosed |
| WO-1997024117-A1 | SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-10 | — | — | WO | disclosed |
| US-5576323-A | CENTRAL NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY (US) | 1996-11-19 | — | — | US | disclosed |
| CN-1108240-A | Excitatory amino acid receptor antagonists | LILLY CO ELI (US) | 1995-09-13 | — | — | CN | disclosed |
| EP-0658539-A1 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 1995-06-21 | — | — | EP | disclosed |
| US-5331103-A | Reaction with hydrogen peroxide, hydroquinone from phenol | RHONE-POULENC CHIMIE (FR) | 1994-07-19 | — | — | US | disclosed |
| EP-0558376-A1 | Method of monohydroxylating phenolic compounds | RHONE-POULENC CHIMIE (FR) | 1993-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200246365-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AS INHIBITORS OF RAN GTPASE | RAN, RANBP1, GDI2 | TDP1 2516/4885NPC1 101/4885CASP3 3865/4885 |
| US-20230302030-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AS INHIBITORS OF RAN GTPase | RAN, RANBP1, GDI2 | TDP1 2516/4885NPC1 101/4885CASP3 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.